ilaris

• Product Code: ilaris

• Ilaris (canakinumab) is a fully human IgG1 monoclonal antibody designed to bind selectively to IL‑1β and block its interaction with IL‑1 receptors, thereby dampening inflammatory pathways driven by this cytokine Administered as a subcutaneous injection (typically 150 mg or weight-based dosing), it has a half-life of approximately 26 days with peak blood concentrations reached around one week post-injection

  Approved Uses Include:

  • Cryopyrin-Associated Periodic Syndromes (CAPS): Muckle-Wells syndrome, Neonatal-Onset Multisystem Inflammatory Disease (NOMID/CINCA), familial cold urticaria

  • Tumour Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS)

  • Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD)

  • Familial Mediterranean Fever (FMF)

  • Still’s Disease: Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged ≥ 2 years

  • Gout Flares: For adults with frequent attacks who do not respond to or cannot tolerate NSAIDs, colchicine, or steroids

  Mechanism & Benefits:
  Ilaris intercepts IL‑1β, a key inflammatory mediator, reducing symptoms like fever, joint pain, rashes, fatigue, and systemic inflammation. Clinical trials show rapid improvement—typically within 7 days—with over 70% of CAPS patients responding fully by this time and 97% by eight weeks

  Administration & Safety Profile:

  • Given under the skin by a healthcare provider every 4–8 weeks, depending on indication

  • Common side effects include upper respiratory infections, injection-site reactions, headache, nausea, abdominal pain, and sometimes vertigo 

  • Serious risks include increased susceptibility to infections (including TB) and rare hypersensitivity events. Live vaccines are contraindicated during treatment, and TB screening is required before starting therapy

  Pharmacokinetics & Efficacy Monitoring:

  • Peak serum levels occur ~7 days post-dose; half‑life ~26 days; bioavailability ~66%

  • Biomarkers like C‑reactive protein (CRP) and Serum Amyloid A (SAA) typically normalise within days of treatment

• Availability: In Stock

• American Diabetes Association

• Diabetes Disaster_Response Coalition storing insulin

• FDA Approved Prescription